Publication at Faculty of Medicine in Hradec Králové |
2010
Abstract
The newest oral anticoagulants, dabigatran and rivaroxaban, have been approved in more than 70 countries for prevention of venous thromboembolism after elective hip or knee arthroplasty. Evidence based guidelines recommend anticoagulant thromboprophylaxis with subcutaneous agents such as low molecular weight heparin (LMWH) or fondaparinux or oral agents such as warfarin, dabigatran, or rivaroxaban for at least 10 days after knee arthroplasty and for up to 35 days after hip arthroplasty.
Author is describing the advantages and disadvantages of the new oral anticoagulants compared with low molecular weight heparin, fondaparinux, and warfarin
